EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma) (vol 9, pg 503, 1999)



Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma) (vol 9, pg 503, 1999)








(PDF emailed within 1 workday: $29.90)

Accession: 021380867

Download citation: RISBibTeXText



Related references

Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma). Melanoma Research 9(5): 503-509, 1999

Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. Melanoma Research 9(5): 503-509, 1999

Phase II study of interferon alfa-2a and dacarbazine in advanced melanoma. Biological Response Modifiers in Melanoma (BREMIM) Italian Cooperative Group. European Journal of Cancer 28a(10): 1719-1720, 1992

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. Journal of Clinical Oncology 23(27): 6747-6755, 2005

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. British Journal of Cancer 77(8): 1280-1286, 1998

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. Journal of Clinical Oncology 17(3): 968-975, 1999

Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. Journal of Clinical Oncology 20(6): 1600-1607, 2002

Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Research 3(2): 133-138, 1993

Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. Journal of Cancer Research and Clinical Oncology 125(5): 292-296, 1999

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 26(35): 5748-5754, 2008

Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study. American Journal of Clinical Oncology 25(5): 460-463, 2002

Randomized phase II trial of BCDT (carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifens) with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. British Journal of Cancer 77(8): 1280-1286, 1998

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. British Journal of Cancer 82(6): 1158-1162, 2000

Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma: A randomised phase III trial. European Journal of Cancer 34(9): 1368-1374, 1998